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Quantitative real-time PCR. For quantitative analysis of genomic DNA and mRNA in patient samples, 30 ng genomic DNA and 2 g mRNA were used, respectively. mRNA was reversetranscribed, using Super Script 2 (Invitrogen) with random primer. qRT-PCR was carried out with SYBR Green PCR master mix (Applied Biosystems) and gene specific primers listed (Supplementary Table 3 ) on ABI PRISM 7900HT. We compared the normalized the CT values using the housekeeping gene -actin.
Cell culture and transfection. The Jurkat E6.1 (human T cell acute lymphoblastic leukemia), H9 (human cutaneous T lymphocyte lymphoma) and HUT78 (human cutaneous T lymphocyte lymphoma) cell lines obtained from the American Type Culture Collection (ATCC) were maintained in RPMI-1640 medium containing 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin and 250 ng/ml amphotericin B at 37 °C and 5% CO2. Cultured cells were regularly tested for mycoplasma infection using the MycoAlert mycoplasma detection kit (Lonza). To generate expression vector plasmids for CTLA4 and CTLA4-CD28 fusion, cDNA encoding CTLA4 and CD28 were amplified by PCR from appropriate sources and inserted into LZRSpMBN linker IRES EGFP vector. Plasmids expressing CTLA4 and CTLA4-CD28 fusion were transfected into cells using the Nucleofector I device (Amaxa) with Nucleofector solution V and program X-001 (Jurkat) and G-014 (H9). Typically, one million cells were transfected with 2 μg of plasmid. A GFP-expressing plasmid was used to measure transfection efficiency.
Expression of CTLA4 and CTLA4-CD28 fusion proteins was analyzed by flow cytometry.
Transfected cells were stained with PE-Cy7 CD28 (CD28.2, BD pharmingen) and PE-Cy5 CTLA4 (BNI3, BD pharmingen) for 30 min and analyzed using FACS Verse (BD bioscience). and CTLA4-CD28 fusion signaling, cells transfected with indicated plasmids were treated with 2 μg/ml mouse anti-human CD28 (BD Pharmingen), 2 μg/ml mouse anti-human CTLA4 (BD Pharmingen) or normal 2 μg/ml rabbit IgG for 10 min on ice, followed by crosslinking with 5 μg/ml goat anti-mouse IgG or goat anti-rabbit IgG (Ab frontier) for 10 min on ice. Then cells were incubated at a 37°C for 1 hour and lysed. Equal amounts of cell lysates were subjected to SDS-PAGE, transferred and probed with antibody. Equal protein loading was assessed by immunoblotting for α-tubulin. were removed. We further filtered out mutations of germline origin using exome sequencing data for paired samples of tumor and matched normal samples from 5 AITL patients, 100 lung cancer patients, 50 gastric cancer patients in Korean population (in-house data). Finally, we confirmed the mutation by Sanger sequencing for cases when patient samples were available. We have thus identified 3 novel cases of point mutations (CD28_F51I, TCF3_G302S, and KMT2D_S4251F).
Library
Loss-of-function mutations in TET2 gene are prevalent in myeloid cancers and lymphoma. Thus, a careful analysis of indels leading to loss-of-function is essential, especially for the sequencing data with homopolymer problem. Through a careful evaluation, we determined reliable indels as (i) no.
with patient recurrency over 10% turned out to be false positives in most cases. Among 182 indels from the GATK HaplotypeCaller predictions on TET2 gene, we have obtained 7 indels satisfying both conditions. In addition, 24 missense mutations were predicted in TET2 gene, 6 of which were filtered out as SNPs with population diversity and additional 11 candidates were nondamaging according to ANNOVAR annotation, leaving 7 missense mutations of functional consequences. Including 10 nonsense mutations, the number of loss-of-function mutations in TET2 gene was 24 (7 misssense mutations, 10 nonsense mutations, 7 indels), 19 of which had been previously reported in hematological tumors (Supplementary Fig. S9 ). Five mutations (E1151X, 1715-1717del, 1747-1751del, Y1148D, G1861V) were novel from our study, and The fusion products from CEMC1-15 and CEMC7-14 cells were shorter due to the partial deletion in the exon 2 of CTLA4 gene (391-457 bp region). This is a frame-shift deletion that would lead to loss-of-function of the fusion transcript. Thus, the fusion transcript is expected to play no active functional role in these cell lines.
Supplementary Fig. S2 . Validation of the CTLA4-CD28 fusion gene in patients. Fusion transcripts were validated by RT-PCR using FFPE samples from TCL patients. Arrows indicate the approximate positions of oligonucleotide primers on the CTLA4-CD28 fusion transcript. PCR products were validated by Sanger sequencing. -actin was used as an internal control, and NTC indicates the no template control. Supplementary Fig. S3 . Functional analyses of the CTLA4-CD28 fusion gene in H9 cell line. (a) In vitro proliferation assay in H9 cells. H9 cells expressing the CTLA4-CD28 fusion show enhanced cell proliferation (*P < 0.05 compared with cells expressing wild-type CTLA4) after co-stimulation with anti-CD3/CTLA4 antibodies. Each experiment was repeated three times with five replicates, and the data are expressed as the mean ± standard deviation. (b) Expression of the CTLA4-CD28 fusion enhanced interleukin 2 (IL-2) production after CTLA4 activation (**P < 0.01 compared with cells expressing wild-type CTLA4). H9 cells were stimulated with PMA/Ionomycin (P/I) without or with anti-CD3/CTLA4 antibodies to activate CTLA4. IL-2 measurement was carried out three independent times, and the data are expressed as the mean ± standard deviation. Supplementary Fig. S5 . Fluorescence in situ hybridization analysis for the fusion. Metaphase chromosome of normal cells without fusion showed two orange signals which indicated merged green and red signal derived from closely located CD28 and CTLA genes, respectively. The cells with fusion showed two orange signals as well. There was no separate signal indicating the presence of episomal fusion gene. This does not rule out the possibility of episome formation in all fusion-positive cases.
Supplementary Fig. S6 . Copy number analysis of CD28 and CTLA4 genes in fusion negative and positive TCL patients. Copy number change was estimated relative to that in the peripheral blood cells from a normal individual. Quantitative real time PCR was carried out using multiple primer pairs covering genomic loci of CD28 and CTLA4 genes. -actin was used as a normalizing control. Four out of five primer pairs within the fusion region showed significant copy number gains in fusion-positive patients. Results from two representative primer pairs (CD28_gQ5 and CTLA4_gQ1) were shown in Fig. 3b . The fusion regions are indicated by the bracket at the top, and the primer positions are indicated by the bars at the bottom. Cases of statistically significant copy number gain are indicated by the asterisks (P-value < 0.05).
Supplementary Fig. S7 . Sanger sequencing of genomic DNA for mapping exact fusion points.
In Case 1, a LINE element of 47 bp long was identified between the fusion introns. Cases 3-6 and two cell lines are examples of direct joining of two exons. Vertical bars indicate the break points.
